Update on antiplatelet agents, including match, charisma, and esprit

Current Cardiology Reports

Volumn 10, Issue 1, 2008, Pages 9-16

  Skliut, Maryna ^a   Jamieson, Dara G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ACETYLSALICYLIC ACID PLUS WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; HEMATOLOGIC AGENT; PLACEBO; SIMVASTATIN; TELMISARTAN; UNCLASSIFIED DRUG; WARFARIN; DRUG DERIVATIVE; TICLOPIDINE;

BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CORONARY ARTERY DISEASE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; REVIEW; RISK REDUCTION; TRANSIENT ISCHEMIC ATTACK; VASODILATATION; BRAIN ISCHEMIA; FEMALE; MALE; RISK FACTOR;

ASPIRIN; BRAIN ISCHEMIA; CORONARY ARTERY DISEASE; DIPYRIDAMOLE; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TICLOPIDINE;

EID: 44449167632     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-008-0004-6     Document Type: Review

References (33)

1. Rosamond W, Flegal K, Friday G, et al.: Heart disease and stroke statistics-2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115: E69-e171.
2. Bellavance A: Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The Ticlopidine Aspirin Stroke Study. Stroke 1993, 24: 1452-1457.
3. Gorelick PB, Richardson D, Kelly M, et al.: Aspirin and ticlopidine for prevention of recurrent stroke in black patients: A randomized trial. JAMA 2003, 289: 2947-2957.
4. Ticlopidine Aspirin Stroke Study Group: Ticlopidine versus aspirin for stroke prevention: On-treatment results from the ticlopidine aspirin stroke study. J Stroke Cerebrovasc Dis 1993, 3: 168-176.
5. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al.: Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998, 128: 541-544.
6. Culebras A, Rotta-Escalante R, Vila J, et al.: Triflusal vs aspirin for prevention of cerebral infarction: A randomized stroke study. Neurology 2004, 62: 1073-1080.
7. MurdoAh D, Plosker GL: Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation. Drugs 2006, 66: 671-692.
8. Matías-Guiu J, Ferro JM, Alvarez-Sabín J, et al.: Comparison of triflusal and aspirin for prevention of vascular events in patients afAer cerebral infarction: The TACIP Study: a randomized, double-blind, multicenter trial. Stroke 2003, 34: 840-848.
9. Matsumoto M: Cilostazol in secondary preIention of stroke: impact of the Cilostazol Stroke Prevention Study. Atheroscler Suppl 2005, 6: 33-40.
10. Uchiyama S, Ozaki Y, Satoh K, et al.: Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study. Cerebrovasc Dis 2007, 24: 264-270.
11. Diener HC, Cunha L, Forbes C, et al.: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143: 1-13.
12. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee [no authors listed]. Lancet 1996, 348: 1329-1339.
13. Markus HS, Droste DW, Kaps M, et al.: Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: The Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005, 111: 2233-2240.
14. Diener HC, Bogousslavsky J, Brass LM, et al.: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004, 364: 331-337.
15. Bhatt DL, Topol EJ: Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004, 148: 263-268.
16. Bhatt DL, Fox KAA, Hacke W, et al.: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006, 354: 1706-1717.
17. Halkes PH, van Gijn J, Kappelle LJ, et al.: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet 2006, 367: 1665-1673.
18. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): A randomised controlled trial. The ESPRIT Study Group [no authors listed]. Lancet Neurol 2007, 6: 115-124.
19. Lutsep HLI MATCH results: implications for the internist. Am J Med 2006, 119: 526.e1-526.e7.
20. Wang TH, Bhatt DL, Fox KA: An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J 2007, 28: 2200-2207.
21. Albers GW: Can the ESPRIT results end the antiplatelet battle between neurologists and cardiologists? Nat Clin Pract Cardiovasc Med 2007, 4: 118-119.
22. Jamieson DG, Parekh A, Ezekowitz MD: Review of antiplatelet therapy in secondary prevention of cerebrovascular events: A need for direct comparisons between antiplatelet agents. J Cardiovasc Pharmacol Ther 2005, 10: 153-161.
23. Sacco RL, Adams R, Albers G, et al.: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke 2006, 37: 577-617.
24. Albers GW, Hart RG, Lutsep HL, et al.: AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: A statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke 1999, 30: 2 502-2 511.
25. Albers GW, Amarenco P, Easton JD, et al.: Antithrombotic and thrombolytic therapy for ischemic stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126: 483S-512S.
26. Johnston SC, Nguyen-Huynh MN, Schwarz ME, et al.: National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol 2006, 60: 301-313.
27. Sacco RL, Sivenius J, Diener HC: Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. Arch Neurol 2005, 62: 403-408.
28. Diener HC, Sacco R, Yusuf S: Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007, 23: 368-380.
29. Pullicino P, Thompson JL, Barton B, et al.: Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): Rationale, objectives, and design. J Card Fail 2006, 12: 39-46.
30. Tran HA, Anand SS, Hankey GJ, Eikelboom JW: Aspirin resistance. Thromb Res 2007, 120: 337-346.
31. Hankey GJ, Eikelboom JW: Aspirin resistance. Lancet 2006, 367: 606-617.
32. Anand S, Yusuf S, Xie C, et al.: Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007, 357: 217-227.
33. Liao JK: Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer? Circulation 2007, 115: 1615-1621.